Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Zosano Pharma Corporation    ZSAN

ZOSANO PHARMA CORPORATION

(ZSAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Zosano Pharma : FDA declines to approve Zosano's treatment for relieving migraine headaches

10/21/2020 | 08:40am EST

Oct 21 (Reuters) - The U.S. Food and Drug Administration on Wednesday declined to approve Qtrypta, Zosano Pharma Corp's experimental treatment to relieve pain after the onset of migraine headaches, citing issues with the drug delivery during clinical trials.

The decision comes after the agency in September raised similar concerns with the company's marketing application for the treatment. (Reporting by Amruta Khandekar and Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)


© Reuters 2020
All news about ZOSANO PHARMA CORPORATION
11/17ZOSANO PHARMA : Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
11/16ZOSANO PHARMA : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/16Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
11/16ZOSANO PHARMA : Reports Third Quarter 2020 Financial Results
AQ
11/13ZOSANO PHARMA CORP : Results of Operations and Financial Condition, Notice of De..
AQ
11/13ZOSANO PHARMA : Management's Discussion and Analysis of Financial Condition and ..
AQ
11/13ZOSANO PHARMA : Reports Third Quarter 2020 Financial Results
AQ
11/13Zosano Pharma Reports Third Quarter 2020 Financial Results
GL
11/11ZSAN SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Zosano Pharm..
BU
11/08ZOSANO PHARMA : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Zosano Pharma Corporatio..
BU
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -33,6 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 62,8 M 62,8 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 18,3x
Nbr of Employees 56
Free-Float 99,6%
Chart ZOSANO PHARMA CORPORATION
Duration : Period :
Zosano Pharma Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZOSANO PHARMA CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,83 $
Last Close Price 0,62 $
Spread / Highest target 225%
Spread / Average Target 198%
Spread / Lowest Target 144%
EPS Revisions
Managers
NameTitle
Steven Lo President, Chief Executive Officer & Director
John P. Walker Chairman
Hayley Lewis Senior Vice President-Operations
Christine Matthews Chief Financial Officer
Donald J. Kellerman VP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZOSANO PHARMA CORPORATION-59.53%67
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE266.71%29 915